Biogen IDEC Inc.

BIIB-Q

NASDAQ:BIIB

286.51
0.37 (0.13%)
Biogen, Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurodegenerative, ...
More at Wikipedia

Analysis and Opinions about BIIB-Q

Signal
Opinion
Expert
DON'T BUY
DON'T BUY
September 24, 2019
The sector has done poorly, and the summer is seasonality. A lot of this has to do with the US election campaign with candidates offering cheap/free healthcare. BIIB fell below support at $250. He is avoiding the entire space.
Show full opinionHide full opinion
Biogen IDEC Inc. (BIIB-Q)
September 24, 2019
The sector has done poorly, and the summer is seasonality. A lot of this has to do with the US election campaign with candidates offering cheap/free healthcare. BIIB fell below support at $250. He is avoiding the entire space.
SELL
SELL
May 15, 2019
He doesn't like their chart. Sell if it closes below $220. Institutions are selling it, and it's selling on weak volume. Had a big breakdown in latter 2018. Look elsewhere.
Show full opinionHide full opinion
He doesn't like their chart. Sell if it closes below $220. Institutions are selling it, and it's selling on weak volume. Had a big breakdown in latter 2018. Look elsewhere.
Javed Mirza

Unlock Ratings

Price
$230.590
Owned
Unknown
COMMENT
COMMENT
May 3, 2019
Demonstrates how binary risk can happen in individual securities. Big driver recently has been failure in an Alzheimer's study. Had to shut the study down, which caught the market by surprise. Likes it, though risk in this stock is high, with a relatively high rate of return. For all large cap biotech, make sure you have at least a couple of positions.
Show full opinionHide full opinion
Demonstrates how binary risk can happen in individual securities. Big driver recently has been failure in an Alzheimer's study. Had to shut the study down, which caught the market by surprise. Likes it, though risk in this stock is high, with a relatively high rate of return. For all large cap biotech, make sure you have at least a couple of positions.
DON'T BUY
DON'T BUY
March 22, 2019
Indicators are quite oversold. Lots of action around $219 from 2013. He very rarely plays individual biotech names for this very reason. It's high beta, so it's more volatile than the market. He prefers to buy the biotech ETF. If it breaks $198, it will probably go to $150.
Show full opinionHide full opinion
Indicators are quite oversold. Lots of action around $219 from 2013. He very rarely plays individual biotech names for this very reason. It's high beta, so it's more volatile than the market. He prefers to buy the biotech ETF. If it breaks $198, it will probably go to $150.
TOP PICK
TOP PICK
July 17, 2018

A large bio-pharma. They enjoyed a recent jump in the stock price had to do with seeing promising results from a phase 2 trial drug treating Alzheimer's. If this drug ultimately passes, it would be an multi-billion-dollar opportunity. Free cash flow is a high 7%. They'll likely make an acqusition with all this cash to deepend their portfolio. (Analysts' price target: $365.00)

Show full opinionHide full opinion

A large bio-pharma. They enjoyed a recent jump in the stock price had to do with seeing promising results from a phase 2 trial drug treating Alzheimer's. If this drug ultimately passes, it would be an multi-billion-dollar opportunity. Free cash flow is a high 7%. They'll likely make an acqusition with all this cash to deepend their portfolio. (Analysts' price target: $365.00)

DON'T BUY
DON'T BUY
May 3, 2018

He Prefers VRTX-Q. You need to invest in the most innovative companies in this sector.

Show full opinionHide full opinion

He Prefers VRTX-Q. You need to invest in the most innovative companies in this sector.

PAST TOP PICK
PAST TOP PICK
March 14, 2018

A situation where the market is nervous, the stock slips, which then creates opportunity. Investors won't pay these kinds of multiples out of uncertainty. Biogen is focussed on developing solutions for MS; their Alzheimer's drug is in phase 3 testing, which he personally hopes works. Be patient. BIIB will bounce around with failed drug tests, but this company will yield winning drugs.

Show full opinionHide full opinion

A situation where the market is nervous, the stock slips, which then creates opportunity. Investors won't pay these kinds of multiples out of uncertainty. Biogen is focussed on developing solutions for MS; their Alzheimer's drug is in phase 3 testing, which he personally hopes works. Be patient. BIIB will bounce around with failed drug tests, but this company will yield winning drugs.

BUY
BUY
March 14, 2018

He loves when good companies pullback in price. He would be tempted to buy here and more if it fell to $240. His model price is $402.

Show full opinionHide full opinion

He loves when good companies pullback in price. He would be tempted to buy here and more if it fell to $240. His model price is $402.

PARTIAL SELL
PARTIAL SELL
October 2, 2017

Seasonal strength is from May until the end of September. It is an opportunity to take some money off the table.

Show full opinionHide full opinion

Seasonal strength is from May until the end of September. It is an opportunity to take some money off the table.

Don Vialoux

Unlock Ratings

Price
$316.170
Owned
Unknown
DON'T BUY
DON'T BUY
September 14, 2017

It has a large franchise in MS which comprises 75% of their business. He is seeing potential threat to this franchise from two companies. Their Alzheimer’ drug comes to trial in 2019 and has high risk.

Show full opinionHide full opinion
Biogen IDEC Inc. (BIIB-Q)
September 14, 2017

It has a large franchise in MS which comprises 75% of their business. He is seeing potential threat to this franchise from two companies. Their Alzheimer’ drug comes to trial in 2019 and has high risk.

COMMENT
COMMENT
June 28, 2017

US healthcare for the long-term? As opposed to picking just one stock in a sector, your best bet probably is an ETF. If you are looking for an individual stock, one that he holds is Biogen. It is quite cheap relative to its ability to grow earnings.

Show full opinionHide full opinion

US healthcare for the long-term? As opposed to picking just one stock in a sector, your best bet probably is an ETF. If you are looking for an individual stock, one that he holds is Biogen. It is quite cheap relative to its ability to grow earnings.

COMMENT
COMMENT
May 10, 2017

He doesn’t own this because of their concentration in the MS market. There are 2 other companies in this area with possible better drugs. He feels there are going to be very binary outcomes with no dividends. Prefers something with a little more diversity.

Show full opinionHide full opinion

He doesn’t own this because of their concentration in the MS market. There are 2 other companies in this area with possible better drugs. He feels there are going to be very binary outcomes with no dividends. Prefers something with a little more diversity.

TOP PICK
TOP PICK
March 16, 2017

A bio pharmaceutical. If you look at the traditional Pharma space, the chemical-based companies, the bio-based companies were always out there, coming along, but basically not making a lot of money and were often single drug companies, virtually reinvesting all their cash flow. They have now matured and into much stronger growth companies than the traditional pharmas. They also have lower multiples than they did 5-6 years ago. That makes it quite attractive. (Analysts’ price target is $305.)

Show full opinionHide full opinion

A bio pharmaceutical. If you look at the traditional Pharma space, the chemical-based companies, the bio-based companies were always out there, coming along, but basically not making a lot of money and were often single drug companies, virtually reinvesting all their cash flow. They have now matured and into much stronger growth companies than the traditional pharmas. They also have lower multiples than they did 5-6 years ago. That makes it quite attractive. (Analysts’ price target is $305.)

HOLD
HOLD
November 22, 2016

(Market Call Minute.) Many people thought the Biotech sector would behave better if Trump got elected. It has had a lift, but it remains to be seen if it can be followed through.

Show full opinionHide full opinion
Biogen IDEC Inc. (BIIB-Q)
November 22, 2016

(Market Call Minute.) Many people thought the Biotech sector would behave better if Trump got elected. It has had a lift, but it remains to be seen if it can be followed through.

BUY
BUY
August 15, 2016

(Market Call Minute.) One of the better growth stories in the US biotech side. They have more of a product portfolio and they have cash. Valuation is in line with the market.

Show full opinionHide full opinion

(Market Call Minute.) One of the better growth stories in the US biotech side. They have more of a product portfolio and they have cash. Valuation is in line with the market.

Showing 1 to 15 of 27 entries